The 340B program requires manufacturers to give hospitals serving large low income populations mandated discounts on outpatient drugs. Lilly says it needs dispensing claims to stop 'duplicate discounts,' and hospitals say the demand itself is unlawful.
The federal 340B drug pricing program requires manufacturers to offer outpatient medicines at mandated discounts to hospitals that serve large shares of low-income patients, with the savings meant to underwrite uncompensated care. Eli Lilly has begun cutting off those discounts at a handful of 340B hospitals, and the move is now testing whether that safety net holds.
Lilly informed a few dozen 340B hospitals that it was eliminating their price breaks because the hospitals failed to provide the comprehensive claims data the company has been demanding, according to a June 18 Pharmalot column by STAT News reporters Ed Silverman and Tara Bannow. The action follows an earlier warning from Lilly this month that it would take such steps if hospitals did not comply.
Lilly frames the request as anti-fraud work. The company says it needs dispensing claims data to identify "duplicate discounts," the situation in which the same drug is counted once for a 340B price break and again for a Medicaid rebate. Without that data, Lilly argues, it cannot tell when it is being asked to give the same discount twice.
Hospital trade groups see the demand itself as the problem. They told STAT that handing over claims data on the scale Lilly wants is technically and financially punishing, particularly for safety-net providers already operating on thin margins, and they argue that the data demand sits outside what federal regulators have authorized. Major hospital trade groups, including 340B Health and the American Hospital Association, have pushed back on the move, calling it a unilateral rewrite of program rules that Congress and the Health Resources and Services Administration (HRSA), the federal agency that administers 340B, never approved.
What makes this more than a billing dispute is the patient math underneath it. At hospitals that rely on 340B, the savings typically underwrite oncology infusions, insulin for uninsured diabetics, Humira-class biologics for rheumatoid arthritis, and the staff time to run charity-care programs. Lose the discount at a given site, and the bill changes: the hospital either absorbs the cost, the program gets cut, or patients are routed elsewhere. None of those outcomes is automatic, but each is now on the table at the hospitals Lilly has targeted.
The open questions are larger than any one manufacturer. Will Congress insert itself before more hospitals get cut off? Will other large drugmakers adopt Lilly's playbook, treating the data demand as the new cost of doing business with 340B hospitals, or will they wait to see whether Lilly absorbs enough political and reputational damage to deter copycat moves? And what happens at the affected sites in the interim, where insulin, cancer drugs, and other discounted therapies may have to be re-ordered, re-priced, or referred out before any of the policy fights resolve?
What to watch next: whether any noncompliant hospital publicly contests the cutoff through HRSA's dispute resolution process, whether Congress holds hearings or issues guidance before the next round of cuts, and whether patients at the affected sites start to see changes in which drugs are stocked or referred out.